ClearPoint Neuro Q2 revenue $7.9M (+32% YoY); raises FY2024 guidance to $30-33M

ClearPoint Neuro, Inc.

2024-Q2 EPS reported -$0.32 revenue$15,497,000

Record quarterly revenue of $7.9M, up 32% YoY; product revenue more than doubled to $4.9M.
Gross margin improved to 63% from 53% a year ago; operating cash burn reduced 47% to $2.7M.
Raised FY2024 revenue guidance to $30-33M from prior; cash position $32.8M after public offering.
Activated 6 new global centers in Q2 (14 YTD); SmartFrame OR and Prism Laser Therapy launched.
Seven pharma partners received expedited FDA review; SmartFlow Cannula approved in Taiwan.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.